Valeant Pharmaceuticals (NYSE: VRX) has announced the return of Michael Pearson as chief executive following his recovery from severe pneumonia.
The company, which produces a range of pharmaceutical products primarily in dermatology, gastrointestinal disorder, eye health neurology and branded generics, said interim chief executive Howard Schiller will continue as a board member after handing back the reigns.
Mr Pearson said: "I want to express my sincere gratitude to Howard for his willingness to step in and lead the company through a challenging period. I realize that recent events are disappointing to everyone and it is my responsibility to set the appropriate tone for the organization. My immediate priority will be to build stronger relationships with important constituents, such as managed care and other channel partners, regulators and government representatives, while improving Valeant's reporting procedures, internal controls and transparency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze